With the recent discovery of induced cellular dormancy associated with ET and CDK4/6i treatment of BC cells, it is no surprise that most BC patients who receive ET and CDK4/6i eventually relapse, even decades after the treatment period [9, 102]. This evidence concerns the gene CDK4 and breast cancer.